No insider purchase over the last 90 days. The latest, by Jaideep Mallick, was filed 04 Oct 2023.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Cipla Limited Buy (bullish), based on 36 analysts. Average price target: ₹1,512.19.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
25 of 35 declarations
The Cipla Limited record is small: 35 filings, 22 of them in 2021, and modest amounts. The 4 purchases total EUR 24,410 (median EUR 4,839), the 3 sales EUR 110,623 (median EUR 33,974). The largest sale, EUR 51,874, is Anusha Jain's on August 12, 2024; the same name also filed EUR 33,974 on August 21, 2024, and Anusha Dinesh Jain EUR 24,776 on March 11, 2022.
On the purchase side, Vidya Prabhakar Rote jointly with Kiran Rote filed EUR 12,639 on December 21, 2022, and Priyanka Mallick EUR 6,993 on August 10, 2023 then EUR 2,684 on September 22, 2023. On August 10, 2023, 2 filers bought EUR 9,086. Across the full history, 2 purchase filings are classed as clustered.
Of the 35 filings, 22 are grants and 6 are of another kind. Purchases are 57% of open-market trades. The record is spread over 2021 (22 filings), 2022 (1), 2023 (8), 2024 (2) and 2025 (2), the last published on September 30, 2025. The median publication delay is 2 days.
The Indian pharmaceutical company has a market capitalisation of INR 1,069.7 billion, 31.1% of the capital with insiders and 30 filers. No filing falls in the last twelve months.